Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03877510
Other study ID # IPX203-B16-03
Secondary ID 2018-002234-21
Status Completed
Phase Phase 3
First received
Last updated
Start date April 3, 2019
Est. completion date March 21, 2022

Study information

Verified date June 2023
Source Impax Laboratories, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.


Description:

This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.


Recruitment information / eligibility

Status Completed
Enrollment 419
Est. completion date March 21, 2022
Est. primary completion date March 21, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Successfully completed Study IPX203-B16-02 - Able to provide written informed consent prior to the conduct of any study-specific procedures. - Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit (Visit 1). - Agrees to use a medically acceptable method of contraception throughout the study and for 6 weeks after completing the study. Exclusion Criteria: - Intends to use any doses of Rytary® or Duopa™ during this study. - Plans to use an investigational treatment other than IPX203 during the course of this study. - Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study. - Participants who, in the opinion of the clinical investigator, should not participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IPX203
IPX203 extended release capsules

Locations

Country Name City State
Czechia Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704) Brno
Czechia NEUROHK. s.r.o. (701) Chocen
Czechia Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702) Pardubice
Czechia CLINTRIAL s.r.o. (703) Praha 10
Czechia AXON Clinical. s.r.o. (700) Praha 5
Czechia Neurologicka ordinace FORBELI s.r.o. (706) Praha 6
France CHU de Clermont-Ferrand-Hopital Gabriel Montpied (404) Clermont-Ferrand Cedex 1
France CHU de Montpellier, Hopital Gui de Chauliac (405) Montpellier Cedex 5
France Centre Hospitalier Universitaire de Nice (400) Nice
France Centre d'lnvestigation Clinique 1436- CHU Purpan- Hopital Pierre Paul Riquet (403) Toulouse Cedex 9
Germany Kliniken Beelitz GmbH, neurologisches Fachkrankenhaus fur Bewegungsstorungen/Parkinson (300) Beelitz-Heilstätten Beelitz
Germany Dr. med. Reinhardt Ehret Neuroloqie Berlin Schlobstr. 29 (309) Berlin
Germany St. Josef-Hospital, Universitatsklinik fur Neurologie Klinisches Forschungszentrum fur Neurodegeneration (301) Bochum Gudrunstabe 56
Germany Klinik Haag i. OB Geriatric Hospital Krankenhausstrabe 4 (305) Haag In Oberbayern
Germany Klinikum rechts der lsar der Technischen Universitat Munchen Klinik und Poliklinik fur Neurologie (303) München Ismaningerstrabe
Germany Gemeinschaftspraxis Dr. med. J. Springub/W. Schwarz, Studienzentrum Nordwest (306) Westerstede
Italy Centro Ricerca Parkinson San Raffaele Cassino (601) Cassino Frosinone
Italy Department "G. F. Ingrassia" section of neuroscience - Policlinico "Vittorio Emanuele" (608) Catania Sicily
Italy Università G. D'annunzio CeSi Met (604) Chieti Italy/Chieti/Abbruzzo
Italy Fondazione I st ituto Neurologico Nazionale "C. Mondino" (606) Pavia Italy/Pavia/Lombardia
Italy Azienda Ospedaliero-Universitaria Pisana (602) Pisa Italy/Pisa/Toscana
Italy Department of neuroscience, mental health and sensory system (NeSMOS), "Sapienza" University (603) Roma Italy/Roma/Lazio
Italy IRCCS San Raffaele Pi sana (600) Roma Italy/Roma/Lazio
Italy University of Rome Tor Vergata/Hospital Tor Vergata (605) Roma Lazio
Poland Centrum Medyczne Neuromed (803) Bydgoszcz
Poland Centrum Medyczne Linden (805) Kraków
Poland Krakowska Akademia Neurologii Sp. Zo.o.(802) Kraków
Poland NZOZ Neuromed M. i M. Nastaj Sp.p. (800) Lublin
Poland NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801) Poznan
Poland Neuro-Care Sp. z o.o. sp. k. (804) Siemianowice Slaskie
Poland Centrum Medycme NeuroProtect (806) Warszawa
Spain Germanes Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516) Barcelona
Spain Hospital de Ia Santa Creu i Sant Pau (502) Barcelona
Spain Hospital Universitario Quiron Dexeus (501) Barcelona
Spain Hospital Universitario Vall d'Hebron (505) Barcelona
Spain Policlinica Gipuzkoa, S.A (511) Donostia San Sebastian Gipuzkoa
Spain Hospital General Universitario de Elche (509) Elche Alicante
Spain Hospital Universitario de Ia Princesa (508) Madrid
Spain Hospital Universitario Infanta Sofia(513) Madrid
Spain Hospital Universitario Ramon y Cajal (500) Madrid
Spain Clinica Universidad de Navarra (512) Pamplona Navarra
Spain Hospital Universitari General de Catalunya (504) Sant Cugat Del Vallès Barcelona
Spain Hospital Universitario Virgen del Rocio (503) Sevilla
Spain Hospital Universitari Mutua Terrassa (506) Terrassa Barcelona
Spain Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell (515) Valencia
United Kingdom Imperial College Healthcare NI-lS Trust (200) London
United Kingdom Re:Cognition Health Ltd (202) London
United Kingdom Re:Cognition Health Ltd (205) Plymouth Devon
United States Albany Medical College (139) Albany New York
United States Emory Brain Health Center (110) Atlanta Georgia
United States JEM Research Institute (136) Atlantis Florida
United States University of Colorado Hospital Anschutz Outpatient Pavilion (120) Aurora Colorado
United States Visionary Investigators Network (168) Aventura Florida
United States Parkinson's Disease and Movement Disorders Center of Boca Raton (121) Boca Raton Florida
United States UHealth at Boca Raton (152) Boca Raton Florida
United States Northwestern Medical Group Neurology Clinic (145) Chicago Illinois
United States Ucgni (133) Cincinnati Ohio
United States Cleveland Clinic(144) Cleveland Ohio
United States University Hospitals Cleveland Medical Center (123) Cleveland Ohio
United States Neurology Consultants of Dallas, PA (108) Dallas Texas
United States University of Texas Southwestern Medical Center (143) Dallas Texas
United States NeuroStudies.net, LLC (155) Decatur Georgia
United States Rocky Mountain Movement Disorders (116) Englewood Colorado
United States Inova Neurology- Fairfax (147) Fairfax Virginia
United States Quest Research Institute (103) Farmington Hills Michigan
United States VCU Health- Neuroscience Orthopaedic and Wellness Center(124) Henrico Virginia
United States Infinity Clinical Research LLC (104) Hollywood Florida
United States Houston Methodist Neurological Institute/Movement Disorders Clinic (135) Houston Texas
United States Indiana University Health Neuroscience Center(164) Indianapolis Indiana
United States University of Florida Health Science Center (129) Jacksonville Florida
United States University of Kansas Medical Center (118) Kansas City Kansas
United States Booth Gardner Parkinson's Care Center (112) Kirkland Washington
United States Cleveland Clinic Lou Ruvo Center for Brain Health (142) Las Vegas Nevada
United States Roseman Medical Research Institute / Roseman Medical Group (154) Las Vegas Nevada
United States Clinical Trials, Inc (113) Little Rock Arkansas
United States University of Arkansas for Medical Sciences (117) Little Rock Arkansas
United States Keek School of Medicine of USC/ University of Southern California (106) Los Angeles California
United States Neurology Associates, P.A. (125) Maitland Florida
United States Medical Professional Clinical Research Center, Inc. (163) Miami Florida
United States University of Miami (149) Miami Florida
United States The Vanderbilt Clinic (158) Nashville Tennessee
United States ChristianaCare Neurology Specialists (153) Newark Delaware
United States Hoag Memorial Hospital Presbyterian (134) Newport Beach California
United States SC3 Research-Pasadena (148) Pasadena California
United States St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156) Phoenix Arizona
United States Xenoscience, Inc (102) Phoenix Arizona
United States Parkinson's Disease Treatment Center of Southwest Florida (131) Port Charlotte Florida
United States SC3 Research-Reseda (146) Reseda California
United States Washington University (109) Saint Louis Missouri
United States Inland Northwest Research (119) Spokane Washington
United States Infinity Clinical Research, LLC (105) Sunrise Florida
United States University of South Florida (114) Tampa Florida
United States University of Toledo, Gardner-McMaster Parkinson Center (122) Toledo Ohio
United States The Movement Disorder Clinic of Oklahoma (115) Tulsa Oklahoma
United States Henry Ford West Bloomfield Hospital(100) West Bloomfield Michigan
United States Premiere Research Institute at Palm Beach Neurology (174) West Palm Beach Florida
United States Central DuPage Hospital (151) Winfield Illinois
United States Charter Research (166) Winter Park Florida

Sponsors (1)

Lead Sponsor Collaborator
Impax Laboratories, LLC

Countries where clinical trial is conducted

United States,  Czechia,  France,  Germany,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-Emergent Adverse Events An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study. From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Baseline, Month 9/ET
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD. Baseline, Month 9/ET
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD. Baseline, Month 9/ET
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD. Baseline, Month 9/ET
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD. Baseline, Month 9/ET
Secondary Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD. Baseline, Month 9/ET
Secondary Patient Global Impression of Severity (PGI-S) The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Patient Global Impression of Severity (PGI-S) The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill. Baseline, Month 9/ET
Secondary Percentage of Participants With a PGI-S = 4 and PGI-S = 5 The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Clinical Global Impression of Severity (CGI-S) The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants. Baseline, Month 3, Month 6, Month 9/ET
Secondary Change From Baseline in Clinical Global Impression of Severity (CGI-S) The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants. Baseline, Month 9/ET
Secondary Percentage of Participants With a CGI-S = 4 and CGI-S = 5 The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants. Baseline, Month 3, Month 6, and Month 9/ET
Secondary 39-item Parkinson's Disease Questionnaire (PDQ-39): Total The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in PDQ-39: Total The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. Baseline, Month 9/ET
Secondary Parkinson Anxiety Scale (PAS): Total The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Parkinson Anxiety Scale (PAS): Total The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms. Baseline, Month 9/ET
Secondary Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score. Baseline, Month 9/ET
Secondary Parkinson's Disease Sleep Scale-2 (PDSS-2) Total The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60. Baseline, Month 3, Month 6, and Month 9/ET
Secondary Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60. Baseline, Month 9/ET
Secondary Treatment Satisfaction Assessment (TSA) The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied. Month 3, Month 6 and Month 9/ET
Secondary Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral) The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied. Month 3, Month 6, and Month 9/ET
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Recruiting NCT04788693 - Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A